| Case Number | 8587 |
| Request Date | 11/05/2022 |
| Completion Date | 19/05/2022 |
Details of the Request
1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab
2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab
Details of the Response
Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
| Adalimumab - Humira | 14 |
| Adalimumab Biosimilar | 28 |
| Apremilast | 15 |
| Bimekizumab | 0 |
| Brodalumab | 0 |
| Certolizumab | 1 |
| Dimethyl fumarate | 1 |
| Etanercept - Enbrel | 0 |
| Etanercept Biosimilar | 0 |
| Guselkumab | 10 |
| Infliximab - Remicade | 0 |
| Infliximab Biosimilar | 0 |
| Ixekizumab | 1 |
| Risankizumab | 0 |
| Secukinumab | 21 |
| Tildrakizumab | 0 |
| Ustekinumab | 15 |
Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
| Adalimumab - Humira | 17 |
| Adalimumab Biosimilar | 81 |
| Filgotinib | 0 |
| Golimumab | 0 |
| Infliximab - Remicade | 1 |
| Infliximab Biosimilar | 86 |
| Ozanimod | 0 |
| Tofacitinib | 0 |
| Ustekinumab | 76 |
| Vedolizumab | 8 |



